Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.

Li-Jen Cheng,Lydia Loke,Elaine Hsuen Lim,Fiona Pearce,Mohamed Ismail Abdul Aziz,Kwong Ng

Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.

2021

Li-Jen Cheng
Lydia Loke
Elaine Hsuen Lim
Fiona Pearce
Mohamed Ismail Abdul Aziz
Kwong Ng

This study evaluates the cost-effectiveness of pertuzumab with trastuzumab biosimilar and docetaxel as initial treatment for HER2-positive metastatic breast cancer (MBC) in Singapore. A partitioned...

Keywords:

Pertuzumab
Trastuzumab
Oncology
Docetaxel
Combination therapy
cost effectiveness
Biosimilar
Medicine
Metastatic breast cancer
Breast cancer
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations